483 related articles for article (PubMed ID: 22698404)
21. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
22. Alterations in gene expression and sensitivity to genotoxic stress following HdmX or Hdm2 knockdown in human tumor cells harboring wild-type p53.
Heminger K; Markey M; Mpagi M; Berberich SJ
Aging (Albany NY); 2009 Jan; 1(1):89-108. PubMed ID: 19946469
[TBL] [Abstract][Full Text] [Related]
23. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
24. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines.
Tsao CC; Corn PG
Cancer Biol Ther; 2010 Dec; 10(12):1315-25. PubMed ID: 20953142
[TBL] [Abstract][Full Text] [Related]
25. Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype.
Gottschalk B; Klein A
Mol Cell Biochem; 2013 Jul; 379(1-2):213-27. PubMed ID: 23564067
[TBL] [Abstract][Full Text] [Related]
26. Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage.
Zhu M; Yi M; Kim CH; Deng C; Li Y; Medina D; Stephens RM; Green JE
Genome Biol; 2011 Aug; 12(8):R77. PubMed ID: 21846369
[TBL] [Abstract][Full Text] [Related]
27. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
[TBL] [Abstract][Full Text] [Related]
28. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.
Liu YY; Patwardhan GA; Bhinge K; Gupta V; Gu X; Jazwinski SM
Cancer Res; 2011 Mar; 71(6):2276-85. PubMed ID: 21278235
[TBL] [Abstract][Full Text] [Related]
29. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells.
Zhang X; Gu L; Li J; Shah N; He J; Yang L; Hu Q; Zhou M
Cancer Res; 2010 Dec; 70(23):9895-904. PubMed ID: 20935220
[TBL] [Abstract][Full Text] [Related]
30. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.
Blanco-Aparicio C; Cañamero M; Cecilia Y; Pequeño B; Renner O; Ferrer I; Carnero A
PLoS One; 2010 Feb; 5(2):e9305. PubMed ID: 20174572
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
[TBL] [Abstract][Full Text] [Related]
32. p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours.
Guillot C; Falette N; Paperin MP; Courtois S; Gentil-Perret A; Treilleux I; Ozturk M; Puisieux A
Oncogene; 1997 Jan; 14(1):45-52. PubMed ID: 9010231
[TBL] [Abstract][Full Text] [Related]
33. Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss.
Debies MT; Gestl SA; Mathers JL; Mikse OR; Leonard TL; Moody SE; Chodosh LA; Cardiff RD; Gunther EJ
J Clin Invest; 2008 Jan; 118(1):51-63. PubMed ID: 18060046
[TBL] [Abstract][Full Text] [Related]
34. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
Lin YC; Sun SH; Wang FF
Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax.
Kong W; Jiang X; Mercer WE
Cancer Biol Ther; 2009 Mar; 8(6):555-63. PubMed ID: 19242108
[TBL] [Abstract][Full Text] [Related]
36. c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
Morrison CD; Allington TM; Thompson CL; Gilmore HL; Chang JC; Keri RA; Schiemann WP
Oncotarget; 2016 Nov; 7(45):72777-72794. PubMed ID: 27626309
[TBL] [Abstract][Full Text] [Related]
37. Wnt5a suppresses tumor formation and redirects tumor phenotype in MMTV-Wnt1 tumors.
Easter SL; Mitchell EH; Baxley SE; Desmond R; Frost AR; Serra R
PLoS One; 2014; 9(11):e113247. PubMed ID: 25401739
[TBL] [Abstract][Full Text] [Related]
38. LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53.
Zhou X; Sang M; Liu W; Gao W; Xing E; Lü W; Xu Y; Fan X; Jing S; Shan B
Life Sci; 2012 Sep; 91(9-10):358-63. PubMed ID: 22906635
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation.
Konduri SD; Medisetty R; Liu W; Kaipparettu BA; Srivastava P; Brauch H; Fritz P; Swetzig WM; Gardner AE; Khan SA; Das GM
Proc Natl Acad Sci U S A; 2010 Aug; 107(34):15081-6. PubMed ID: 20696891
[TBL] [Abstract][Full Text] [Related]
40. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.
Ottewell PD; Lefley DV; Cross SS; Evans CA; Coleman RE; Holen I
Int J Cancer; 2010 Jan; 126(2):522-32. PubMed ID: 19621384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
